← All trials
NCT04480762
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2021
- First posted
- Jul 21, 2020
- Last posted
- Jul 21, 2020
- Enrollment
- 42
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.